SCYNEXIS, Inc. (SCYX): Price and Financial Metrics


SCYNEXIS, Inc. (SCYX): $1.87

0.01 (+0.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SCYX POWR Grades


  • SCYX scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.83% of US stocks.
  • The strongest trend for SCYX is in Growth, which has been heading up over the past 179 days.
  • SCYX's current lowest rank is in the Quality metric (where it is better than 4.06% of US stocks).

SCYX Stock Summary

  • SCYX has a market capitalization of $97,955,995 -- more than approximately only 14.67% of US stocks.
  • With a year-over-year growth in debt of 156.49%, Scynexis Inc's debt growth rate surpasses 92.96% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SCYX comes in at -125.07% -- higher than that of only 2.91% of stocks in our set.
  • Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are MYSZ, NAVB, SPNS, SONM, and CYBE.
  • Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.

SCYX Valuation Summary

  • In comparison to the median Healthcare stock, SCYX's price/sales ratio is 11.01% higher, now standing at 12.6.
  • SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.
  • SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.

Below are key valuation metrics over time for SCYX.

Stock Date P/S P/B P/E EV/EBIT
SCYX 2021-08-31 12.6 4.7 -3.4 -1.8
SCYX 2021-08-30 12.2 4.6 -3.3 -1.7
SCYX 2021-08-27 12.3 4.6 -3.3 -1.7
SCYX 2021-08-26 11.9 4.4 -3.2 -1.6
SCYX 2021-08-25 12.1 4.5 -3.2 -1.6
SCYX 2021-08-24 12.3 4.6 -3.3 -1.7

SCYX Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at -75.65%.
  • Its year over year price growth rate is now at -4.72%.
  • Its 2 year revenue growth rate is now at -77.73%.
Over the past 33 months, SCYX's revenue has gone up $12,309,000.

The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 12.566 -45.612 -46.334
2021-06-30 12.05 -38.895 -44.82
2021-03-31 12.05 -36.056 -52.859
2020-12-31 0 -49.354 -55.185
2020-09-30 0 -46.24 -26.932
2020-06-30 0 -46.773 -35.782

SCYX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SCYX has a Quality Grade of C, ranking ahead of 29.3% of graded US stocks.
  • SCYX's asset turnover comes in at 0.134 -- ranking 232nd of 682 Pharmaceutical Products stocks.
  • ACER, QURE, and MNOV are the stocks whose asset turnover ratios are most correlated with SCYX.

The table below shows SCYX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -3.908
2021-03-31 0.169 1 -5.208
2020-12-31 0.000 NA -3.192
2020-09-30 0.000 NA -1.322
2020-06-30 0.000 NA -1.486
2020-03-31 0.001 1 -1.353

SCYX Price Target

For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.36 Average Broker Recommendation 1.36 (Strong Buy)

SCYX Stock Price Chart Interactive Chart >

Price chart for SCYX

SCYX Price/Volume Stats

Current price $1.87 52-week high $8.10
Prev. close $1.86 52-week low $1.70
Day low $1.86 Volume 42,500
Day high $1.91 Avg. volume 247,419
50-day MA $2.11 Dividend yield N/A
200-day MA $4.52 Market Cap 60.92M

SCYNEXIS, Inc. (SCYX) Company Bio


SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.


SCYX Latest News Stream


Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream


Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about Scynexis Inc that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Market forces rained on the parade of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders today, when the analysts downgraded...

Yahoo | February 13, 2022

Maxim Group Reaffirms Their Buy Rating on SCYNEXIS (SCYX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of $11.00. The company's shares closed last Friday at $5.14, close to its 52-week low of $4.21. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.3% and a 18.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. SCYNEXIS has an analyst consensus of Strong Buy, with a price target consensus of $17.83, which is a 249.6% upside from current levels.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Cigna (CI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $200.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Dyadic International (DYAI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Dyadic International (DYAI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Christine Brown on TipRanks | February 11, 2022

Scynexis Aces Ibrexafungerp Late-Stage Study To Prevent Vaginal Yeast Infections

Scynexis Inc (NASDAQ: SCYX ) has announced results from its Phase 3 CANDLE study of oral ibrexafungerp to prevent recurrent vulvovaginal candidiasis (rVVC), also known as vaginal yeast infection. The Company plans to submit a supplemental marketing application to prevent rVVC in 1H of 2022 with anticipated approval by the end of the year. The 260-subject study showed that Full story available on Benzinga.com

Benzinga | February 10, 2022

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo -10.53%
3-mo -51.17%
6-mo -70.96%
1-year -76.30%
3-year -85.28%
5-year -89.78%
YTD -69.34%
2021 -20.26%
2020 -15.93%
2019 89.58%
2018 -79.31%
2017 -27.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4565 seconds.